Adage Capital Partners
DRUG

Adage Capital Partners’s Bright Minds Biosciences DRUG Stock Holding History

Adage Capital Partners’s Portfolio DRUG Stock Details DRUG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$36.2M Buy
495,743
+100,000
+25% +$8.05M 0.06% 320
2025
Q4 		$30.9M Hold
395,743
– – 0.05% 359
2025
Q3 		$24M Buy
395,743
+195,743
+98% +$7.6M 0.04% 415
2025
Q2 		$5.22M Hold
200,000
– – 0.01% 701
2025
Q1 		$7.21M Buy
200,000
+67,500
+51% +$2.47M 0.01% 644
2024
Q4 		$4.77M Buy
+132,500
New +$4.66M 0.01% 722

Other funds holding DRUG

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Adage Capital Partners's DRUG Position: Q1 2026 in Review

Adage Capital Partners increased its Bright Minds Biosciences (DRUG) stake by 25% in Q1 2026, buying an estimated $8.05M and bringing the position to 495,743 shares worth $36.2M. The position accounts for 0.06% of the portfolio, ranked #320.

Adage Capital Partners first reported a position in DRUG in Q4 2024 and has held it in 6 quarters since. 94 funds tracked by Wall St. Rank hold DRUG as of Q1 2026.

  • Adage Capital Partners held 495,743 shares of Bright Minds Biosciences worth $36.2M as of Q1 2026.
  • Adage Capital Partners bought 100,000 Bright Minds Biosciences shares in Q1 2026, an estimated $8.05M.
  • Bright Minds Biosciences made up 0.06% of Adage Capital Partners's portfolio in Q1 2026, its #320 holding.
  • Adage Capital Partners first reported a position in Bright Minds Biosciences in Q4 2024 and has held it in 6 quarters since.
  • 94 funds tracked by Wall St. Rank held Bright Minds Biosciences as of Q1 2026.

Based on Adage Capital Partners's 13F filing for Q1 2026, filed 15 May 2026.